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Abstract
Most candidate anti-bacterials are identified on the basis of their whole cell anti-bacterial activity. A critical bottleneck in the
early discovery of novel anti-bacterials is tracking the structure activity relationship (SAR) of the novel compounds
synthesized during the hit to lead and lead optimization stage. It is often very difficult for medicinal chemists to visualize if
the novel compounds synthesized for understanding SAR of a particular scaffold have similar molecular mechanism of
action (MoA) as that of the initial hit. The elucidation of the molecular MoA of bioactive inhibitors is critical. Here, a new
strategy and routine assay for MoA de-convolution, using a microfluidic platform for transcriptional profiling of bacterial
response to inhibitors with whole cell activity has been presented. First a reference transcriptome compendium of
Mycobacterial response to various clinical and investigational drugs was built. Using feature reduction, it was demonstrated
that subsets of biomarker genes representative of the whole genome are sufficient for MoA classification and deconvolution
in a medium-throughput microfluidic format ultimately leading to a cost effective and rapid tool for routine antibacterial
drug-discovery programs.
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Introduction
Since the early 20th century, bioactive inhibitors used for anti-
infective chemotherapy have been identified by phenotypic screens
and further examined in complex biological systems [1]. Advances
in genome sequencing, molecular biology and biochemistry led to
an evolution from the traditional phenotypic screens to a more
‘reductionist’ target-based approach, which was thought to be
more rational and efficient [2]. Despite the rapid identification of
diverse, novel drug targets characterized by genetic tools [3],
target-based anti-bacterial lead discovery has been less successful
[4–6]. In many cases, these target-based screens reveal small
molecules with potent activity against the purified target in vitro but
fail to render anti-bacterial activity in both in vitro and in vivo
models [4,7].
The large-scale failure of genomics driven anti-bacterial lead
discovery programs has led to the renaissance of empirical
phenotypic screens for the identification of new chemotypes
[6,8,9]. In contrast to target-based screening, molecules identified
using this approach have the advantage of not only possessing
desirable physicochemical properties from the beginning (such as
cell penetration), but are also active against the relevant target in
its intracellular context, under physiological conditions. Despite
this key advantage, success in defining the target, mechanism of
action (MoA), and the final lead optimization of hits derived from
phenotypic screens has been low [4,6].
One of the daunting tasks for medicinal chemists during hit to
lead and lead optimization of hits, and scaffolds derived from
whole cell screen, is to make sure that the compounds they are
synthesizing also have similar MoA as that of the parent molecule.
In order to understand the structure activity and property
relationship (SAR and SPR) medicinal chemists synthesize
multiple compounds in and around the parent molecule. It is
very critical that the new molecules are acting in a similar way as
that of the parent in order to get desired final effect. Currently,
lead optimization of hits from phenotypic screens can only be best
done with a known target. Although various approaches for MoA
and target deconvolution have been established, including
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characterization of resistant mutants, biochemical affinity-based
methods, genetic complementation, protein and DNA microarrays
[10], target identification is still a challenging and inefficient task
to support the early discovery process [6].
Until the last decade, MoA deconvolution was largely limited to
model organisms whose metabolic pathways have been well
characterized. Transcriptional profiling by microarray analysis has
been used to analyze the MoA of early anti-bacterial [11,12], anti-
fungal [13], and anti-malarial compounds [14]. Despite the
elegance of this approach for MoA deconvolution, it is not
practical for use as a routine assay [15–17]. To benefit from the
transcriptional profiling body of evidence we have established a
miniaturized gene expression assay for efficient MoA deconvolu-
tion and discovery chemistry based on microfluidics. The
microfluidic integrated fluidic circuits (IFC) contain tens of
thousands of microfluidic-controlled valves and interconnected
channels for transporting and combining cDNA molecules and
qPCR reagents in complex patterns [18]. As a result of the
miniaturization inherent in this approach, a single assay is capable
of increasing the throughput of traditional qPCR by 2 orders
magnitude using nanolitre reaction volumes compared to the
standard techniques [19]. Here we report the application of this
tool as a routine assay for MoA deconvolution, and its help in hit
to lead and lead optimization of novel compounds obtained by
phenotypic screens. We demonstrate that a minimal number of
differentially expressed genes are sufficient to classify the MoA of
novel chemical entities (NCE).
Materials and Methods
Bacterial cultures and RNA extraction
Mycobacterium tuberculosis (ATCC 27294) and M. bovis BCG
(Pasteur) were grown with aeration at 37uC in Middlebrook 7H9
(Difco) liquid culture medium supplemented with 0.5% (w/v)
bovine serum albumin fraction V, 0.2% dextrose, 0.08% sodium
chloride, 0.5% glycerol, and 0.05%. tween 80 to mid-log phase.
The mid log phase culture was concentrated and re-suspended to
A600 nm of 0.3 (Amersham Ultrospec 3300). Antimicrobial
compounds were added at either 0.56, 16, or 56 minimum
inhibitory concentration (MIC) determined using a turbidimetric
microplate assay. For microarray experiments M. tuberculosis
H37Rv strain was anti-tubercular compounds were treated at
different concentrations for 6 hours prior to isolation of RNA for
analysis. All the details are provided in GEO accession #
GSE46212. For real time qPCR experiments, M. bovis BCG cells
were treated at 0.56MIC50 of various anti-tubercular agents for
3 hours prior to isolation of RNA. For microfluidics experiments,
M. bovis BCG cells were treated at 56 MIC50 of various anti-
tubercular agents for 3 hours prior to isolation of RNA. Dimethyl
sulfoxide (DMSO, drug vehicle) treated mycobacterial cultures
were used as untreated controls in all experiments. The culture of
cells treated/untreated with the inhibitor were pelleted in
RNAlater (Qiagen) and bacterial RNA were extracted using the
GTC/TrizolH method [20].
Figure 1. Cellular transcriptional responses of differentially-expressed genes clustered by inhibitor mechanism of action. A two-way
clustering heat map of chemically perturbed expression profiles using the data from whole genome microarray is shown. Agglomerative clustering
was performed on the 1860 genes differentially expressed in response to the given drug treatments. Profiles were clustered using Euclidean distance
in the similarity matrix. The individual genes are represented on the x- axis and the different drug treatments are indicated on the y-axis (columns).
Red, up-regulation; Blue, down-regulation; White, no change relative to the control. All expression values were transformed to log base 2.
doi:10.1371/journal.pone.0069191.g001
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Table 1. List of investigational and FDA approved anti-tubercular drugs and their mode of action.
Compounds Mode of action BCG MIC50 (mM)
NITD101 Unknown -
NITD102 Unknown -
NCE1a (AD841) Unknown 0.02
NCE1b (AD1015) Unknown 0.04
NCE1c (AD842) Unknown 0.2
NCE2a (AD1158) Unknown 0.38
NCE2b (AD1441) Unknown 1.28
NCE2c (AD1259) Unknown 2.06
NCE2d (AD1260) Unknown 2.04
NCE2e (AD1534) Unknown 7.2
NCE2f (AD1540) Unknown 0.44
NCE3a (NITD_TB034) Unknown 10
NCE3b (ATP425) Unknown 1.6
NCE3c (ATP359) Unknown 6
NCE3d (ATP435) Unknown 2
NCE3e (ATP355) Unknown 10
Cyclomarin- Series Targets the ClpC1 subunit of the Caseinolytic Protease
Liparmycin- Series DNA-dependent RNA polymerase inhibitor
PA-824 Possibly acts via generation of radicals having nonspecific toxic effects. Might possibly target enzymes
in mycolic acid & protein biosynthesis.
0.44
Linezolid Binds to the A site of the 50S subunit, and prevents the assembly of the ribosome initiation complex. 1.52
Ethambutol Cell wall inhibitor, inhibits arabinosyl transferases involved in cell wall biosynthesis. 2.96
Isoniazid Cell wall Inhibitor, Isoniazid inhibits inhA, a NADH-specific enoyl-ACP coA reductase involved in mycolic
acid biosynthesis
0.28
Ethionamide Cell wall inhibitor, disrupts of mycolic acid biosynthesis 2.04
Prothionamide Cell wall inhibitor 0.9
Amikacin Aminoglycosides: Inhibit translocation of the peptidyl-tRNA from the conserved A-site to the P-site
in the 30S ribosomal Subunit.
0.38
Capreomycin 1
Streptomycin 0.16
Kanamycin 1.56
Clofazimine Binds to guanine bases of bacterial DNA, causing steric hindrance in the template function of the DNA.
Causes the accumulation of toxic lysophospholipids which inhibit bacterial growth.
0.26
Ampicillin Penicillin: Beta lactam antibiotic. Penicillins bind to transpetidase enzymes (which are involved in the
continuous remodelling of the peptidoglycan layer by cross linking peptides chains). [Note
transpeptidase catalyses the terminal step of cell wall biosynthesis by cross linking the peptidoglycan].
By inhibiting this enzyme, penicillin prevents the formation of peptide bonds, weakens the cell wall,
which subsequently cause lysis of the cell membrane.
Moxifloxacin Quinolones: Inhibit the bacterial ATP-dependent enzyme DNA gyrase and topoisomerase
IV, preventing DNA unwinding during bacterial replication, transcription and bacterial DNA repair.
0.28
Ofloxacin 1.56
Levofloxacin 0.84
Gatifloxacin 0.2
Sparfloxacin 0.22
Valnemulin Pleuromutilin: Binds to the peptidyl transferase component of the 50S subunit of ribosomes. 6.76
Vancomycin Glycopeptide: Vancomycin binds with high affinity to the D-Ala-D-Ala C-terminus of the pentapeptide,
thereby blocking the addition of late precursors by transglycosylation to the nascent peptidoglycan chain
and preventing subsequent cross-linking by transpeptidation
Rifampicin Inhibits the essential rpoB gene product a subunit of DNA-dependent RNA polymerase activity 0.02
Rifabutin 0.02
Rifapentine 0.02
Thioridazine A phenothiazine interfering with NADH dehydrogenase 14.08
TMC207 Diarylquinoline which inhibits the proton pump of ATP synthase. 0.32
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Quantitative reverse transcription qPCR assay
The expression of genes selected as probes to represent the
whole genome was quantified using real time qPCR, after
normalizing the RNA expression levels to SigA as previously
described [11].
Microarray gene expression
Microarray analysis was performed as described [11]. The
microarray data obtained for the compounds has been submitted
to NCBI (GEO accession # GSE46212 and GPL1343). Expres-
sion ratios were calculated as the feature pixel median minus
background pixel median for one color channel divided by the
same for the other channel. In cases where more than 10% of the
feature pixels were saturated, the feature pixel mean was used
instead of the median. When the feature pixel mean did not
exceed the background pixel mean by more than two standard
deviation values (calculated from the background pixel distribu-
tion), the feature pixel median was used in the ratio without
background subtraction. In cases where both color channels were
near background (same criterion), the ratio value was set to
‘‘missing.’’ Expression ratios were transformed to the log base 2 for
all further calculations.
Microfluidic gene expression analysis
Using the previously described BioMark Fluidigm 96.96
microfluidic chip (Fluidigm, South San Francisco, Calif., USA)
[19], we analyzed bacterial transcriptional response in the
antibiotic or vehicle treated cells. Total RNA was isolated using
Trizol and RNA was quantified using a Nanodrop and adjusted to
150 ng for reverse transcription using High-Capacity RT Kit
(Applied Biosystems, 4368813), as per the manufacture’s recom-
mendations. Pre-amplification of the cDNA was performed using a
Taqman PreAmp Master Mix Kit (Applied Biosystems, 4391128)
as per the manufacture’s recommendations, and the preamplified
product was diluted at 1:20. The pre-amplified product was used
for the BioMark 96.96 Real-time PCR assay (Fluidigm) according
to the manufacture’s recommendations using Eva green DNA
binding dye (Biotium). Fluidigm uses integrated fluidic circuits to
generate a medium throughput for real-time PCR. In the BioMark
platform 96 primer sets and 96 samples can be loaded and via the
on-chip network of microfluidic channels, chambers and valves
individual PCR reactions will be assembled simultaneously (a
maximum of 9,216 reactions can be evaluated at one time). The
complete mechanism of how microfluidic circuit and valve system
technology work have been well described elsewhere (http://www.
fluidigm.com/technology.html).
Data processing and analysis
To identify differentially regulated genes, a measure of
significance t-test was applied to the normalized data set. To
discriminate genes that significantly deviated from the 1:1 ratio
(treated:vehicle), a minimum p-value of 0.05 was used. Differen-
tially expressed genes were subsequently subjected to Benjamini
and Hochberg correction to account for multiple experimental
testing.
Feature reduction
Feature reduction is the process of reducing the number of
variables (in this case genes) defining a condition. Feature
reduction often attempts to identify a minimum set of non-
redundant features that are useful for classification. Microarray
data of mycobacteria treated with a variety of antibacterial
compounds were hierarchically clustered using Euclidian distance
as a distance matrix and a minimal variance method (Ward
linkage) to join adjacent clusters [21]. It can be summarized by the
following five steps: a) Distances between all gene pairs are
calculated, using Euclidean distance, b) The resulting distance
matrix is thoroughly inspected to find the smallest distance
between expression profiles, c) The corresponding genes are joined
together in the tree and form a new cluster, d) The distances
between the newly formed cluster and the other genes are
recalculated, e) Steps b, c and d are iteratively repeated until all
genes and clusters are linked in a final tree.
Table 1. Cont.
Compounds Mode of action BCG MIC50 (mM)
Tetracycline Bind to the 30S ribosomal subunit in the mRNA translation complex thus,
inhibiting binding of aminoacyl-tRNA to the mRNA-ribosome complex.
p-aminosalicylic acid (PAS) Inhibitor of folic acid biosynthesis pathway 0.56
MIC50 listed for anti-tubercular investigational and SAR compounds, when available.
doi:10.1371/journal.pone.0069191.t001
Figure 2. Transcriptional profile of gene clusters in response to antibiotics. X-axis denotes different drugs, and the y-axis denotes relative
expression of the gene in response to the particular drug on the x-axis. Whole genome microarray data were used for this analysis. (A) A cluster
replete with genes in respiratory metabolic pathway as well as subunits of the secretion system. The ESX section associated protein EspC was
selected as the gene best representing the cluster transcription profile. (B) Genes of a related metabolic pathway cluster together in response to
antibiotics. All three genes are from one metabolic pathway. NadB involved in quinolone biosynthesis served as the representative of the cluster.
doi:10.1371/journal.pone.0069191.g002
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A hierarchical cut off was selected that gave 90 gene clusters. A
single biomarker gene to represent each cluster was identified by
finding the gene in the cluster with the best Pearson correlation
against the cluster mean. In total, 90 genes were selected
optimizing the number of biomarkers measured in the 96 probe
fluidigm format while allowing for up to 6 control probes. The
reduction method included following steps; a) computation of
the mean expression of genes in a cluster in all conditions,
b) computation of Pearson product moment correlation co-
efficient to the cluster mean for each gene, and c) the selection
of gene with the best correlation co-efficient in each cluster as the
feature to represent the cluster.
Figure 3. Transcriptional responses to drug treatment reveal that a single gene representing logically associated gene clusters is
sufficient for MoA diagnosis in Mycobacterium tuberculosis. Groups of drugs clustered separately based on the known mechanism of action,
while SAR series of compounds with novel MoA (cyclomarin) showed a fingerprint distinct from any of the compounds tested. Periods following drug
names represent duplicates. X-axis represents the 90 genes that were chosen from the microarray as representative of 90 clusters, y-axis lists the
different drug treatments. i, ii, and iii, represent 3 clusters namely, cell wall inhibitor, RNA polymerase inhibitor and Cyclomarin series, respectively.
doi:10.1371/journal.pone.0069191.g003
Table 2. Pathway enrichment of functional classes of genes on PCR array.
Class ID Functional Class PCR array Genome (H37Rv)
0 Virulence, detoxification & adaptation 10.59% 5.22%
1 Lipid metabolism 5.88% 5.84%
2 Information pathways 7.06% 5.17%
3 Cell wall and cell processes 20% 18.49%
5 Insertion sequences & phages 2.35% 3.62%
6 PPE/PE 3.53% 4.14%
7 Intermediary metabolism & respiration 15.29% 22.11%
9 Regulatory proteins 4.08% 4.78%
10 Conserved hypotheticals 15.29% 22.06%
16 Conserved hypotheticals with an orthologue in M.bovis (BCG) 8.24% 6.43%
- Not annotated on H37Rv 7.06% -
doi:10.1371/journal.pone.0069191.t002
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The robustness of experimental set up was evaluated using
Pearson correlation coefficient of expression values between two
independent biological duplicates. Similarities in the expression
profiles were analyzed by generating heat maps using R [22].
Correlation similarity matrix comparing different compounds, or
SAR analogues was evaluated using both R and the Pearson
product moment correlation coefficient.
Results
A feature reduced compendium of chemical-genetic
profiles
We established the transcriptional response of M. tuberculosis to
12 different inhibitors. Included in this collection were 5 synthetic
compounds and natural products derived from phenotypic
screens, the rest were FDA approved drugs with anti-tubercular
activity. The list of inhibitors used for perturbing bacteria and
MoA diagnosis are included in Table 1. Microarray results showed
differential expression for 1860 genes out of 4734 genes that were
used in the array. (GEO accession # GSE46212 and GPL1343).
The hierarchical heat map of bacterial transcriptional response of
1860 genes to the list of antibacterials showed that groups of drugs
clustered separately based on their known mechanism of action
(Fig. 1). Thus, protein synthesis inhibitors, transcriptional inhib-
itors, cell wall synthesis inhibitors and novel antibacterials fell into
distinct groups. Boshoff and co-workers had previously described
the application of transcriptional profiling using microarrays for
MoA diagnosis of a natural product extract with no known mode
of action [11]. However, the approach is not easily scalable and
suitable for routine MoA diagnosis for hundreds of compounds
from phenotypic screening. To exploit this property amenable for
phenotypic screening, we limited the number of genes defining a
condition to 90 using feature reduction.
Feature reduction and real-time qPCR for MoA
deconvolution
Feature reduction attempts to identify a set of non-redundant
genes that are useful for MoA classification. To reduce the features
amenable to a robust 96 well format, a total of 90 genes from 90
clusters derived from agglomerative hierarchical clustering were
selected. Briefly, the expression profiles of single genes was
successfully joined to form nodes, which in turn were joined
further until a total of ninety clusters were obtained. At the finest
level, redundant gene representations across all perturbations
clustered together with genes in each cluster showing similar
expression profile. Two representative pattern of transcriptional
profile of gene clusters in response to various antibiotics are shown
in Fig. 2A & B. However despite the similar expression patterns,
individual genes could be distinguished from each other with
subtle differences in their expression profiles (Fig. 2A). To reduce
the number of features a single gene was selected from each cluster
that best represented the cluster expression profile by finding the
gene most correlated with the mean expression profile of the
cluster. The 90 genes selected with their known function are listed
in Table S1.
To validate the functionality of the selected gene probes for
MoA diagnosis, we analyzed bacterial transcriptional response to
the chemical perturbation from microarrays. Hierarchical cluster-
ing analysis of the transcription reference compendium revealed
that 90 genes are sufficient to define the MoA of hits derived from
phenotypic screens (Fig. 3). We found that compounds with similar
cellular effects showed similar transcription fingerprints and
thereby cluster together on the vertical axis in revealing both
anticipated and novel insights into their mode-of-action. In
particular there were a couple of examples where the cluster
analysis grouped inhibitors targeting the same pathway or target
(Fig. 3). Individual clusters are annotated by roman numbers: (i)
Cell wall inhibitors: Ampicillin (peptidoglycan) and Isoniazid
Figure 4. Transcriptional responses of M. bovis BCG to anti-tubercular drugs profiled using qPCR. A compendium of qPCR results can
show differences in the MOA of anti-tubercular drugs. (A) Spatial grouping of drug expression profiles on a dendrogram after qPCR profiling using
hierarchical clustering. From the list of drugs tested, two major clusters emerge cell wall inhibitors, and those that inhibit DNA/protein synthesis. (B)
Similarity matrix of expression profiles for chemical inhibitors using qPCR profiling. The blue-red color scale shows the degree of correlation of drugs
expression profiles ranging from 21 to 1 respectively.6- depicts transcriptional responses at 26 or 0.56 the MIC50, while those that have no6
designation were done 16 the MIC50.
doi:10.1371/journal.pone.0069191.g004
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(Mycolic acids); (ii) RNA polymerase inhibitors: Rifampicin and
Lipiarmycin [23], and (iii) a series of ClpC1 caseinolytic
proteasome inhibitors cyclomarin whose mode of action is novel
[24]. The quality of the data was tested using Pearson rank
correlation and Euclidean Distance, which verified that the
expression fingerprint within each compound perturbation was
tightly correlated (Fig. S1).
MoA deconvolution of a natural product with anti-
bacterial activity identified by chemical genetics
Given that, transcriptional profiling is applicable to any
molecule that impairs bacterial growth, we evaluated the MoA
of the natural product cyclomarin. To test whether chemical-
genetic profiling may be particularly useful in driving the SAR for
a molecule whose MoA was distinct from the compendium, we
analyzed the transcriptional fingerprint of different derivatives of
the natural product. All derivatives had a tight correlation,
showing a similar fingerprint suggesting that they all had the same
mode of action, and were probably targeting the same target (Fig. 3
& S1, Fig. 1). A detailed study on the elucidation of the MoA of the
natural product cyclomarin is described elsewhere [24].
To validate the functional representation of the selected
biomarker genes using qPCR, we evaluated the functional
enrichment of genes. Table 2 summarizes the gene function
enrichment of biomarker genes. Functional classes were defined
according to Cole et al [25]. Gene function enrichment revealed
that the dominant feature was a large percentage of virulence,
detoxification and adaptation genes more than twice the expected
number by chance. Genes from this functional class include; a heat
shock protein groES, some conserved hypothetical proteins with
PIN domains, a sub unit of the alkyl-hydrogen peroxide reductase
ahpC involved in the oxidative stress response and genes in toxin-
anti toxin operons. This demonstrates that the feature reduction
can successfully enrich for genes involved in stress responses [26]
as well as central pathways targeted by antibiotics [27].
One of the challenges of working with microarrays for MoA
deconvolution is large sample volume, the need for multiple
replicates, further compounded by the noise inherent in these
systems. As a proof of concept to circumvent these properties,
application of using oligos to PCR amplify the 90 selected genes as
biomarkers to represent the whole genome was evaluated. A small
collection of anti-tubercular drugs were analyzed by qPCR arrays
using M. bovis BCG bacterial RNA. Analysis of the qPCR arrays
showed that expression profiles from this platform were able to
distinguish the MoA between anti-bacterial drugs (Fig. 4A & B).
The minimal gene list to decipher the antibiotic mechanism of
action on a PCR array has been summarized in Table S1.
Figure 5. Hierarchical clustering and correlations of anti-tubercular drugs. Transcriptional responses data obtained from microfluidic
experiment are used for the analysis. The detailed descriptions for genes represented in this figure are provided in Table S1. (A) Hierarchical
clustering via average linkage of Pearson correlations for FDA approved drugs. The individual genes are represented in y-axis and the compound
treatment is in the x-axis. (B) Pearson correlations for 23 anti-tubercular drugs. Correlations were calculated between 2 independent microfluidic
experiments, following median normalization to account for plate effects.
doi:10.1371/journal.pone.0069191.g005
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A medium throughput assay: Microfluidic platform
Despite the excellent dynamic range, sensitivity and reproduc-
ibility of data using real time qPCR, this technique is a low
throughput and expensive method to analyze a limited number of
genes. Microfluidic digital PCR is able to generate higher
throughput data technically identical in quality to the standard
qPCR [19]. We explored the use of microfluidic chips to study the
bacterial transcriptional response to a collection of anti-tubercular
Figure 6. Transcriptional response of selected 90 genes to novel chemical entities. The heatmap was drawn using Pearson correlations
through single linkage for both genes and compound treatments. The individual genes are represented in y-axis and the compound treatment is in
the x-axis. Compounds from the same SAR library (designated as NCE1and NCE2) show a similar expression fingerprint, while NCE3 SAR compound
series displays more variability in expression. The detailed descriptions for genes represented in this figure are provided in Table S1.
doi:10.1371/journal.pone.0069191.g006
Microfluidics as Tool to Study Antimycobacterials
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investigational and 23 FDA approved drugs (Table 1). As
expected, drugs with similar mode of action, targeting the same
cellular organelles clustered together (Fig. 5A). For example the
fluoroquinolines clustered together, which inhibit the bacterial
ATP-dependent enzyme DNA gyrase and topoisomerase IV,
preventing DNA unwinding during bacterial replication, tran-
scription and bacterial DNA repair. To validate the dynamic
microfluidic PCR as a platform for routine gene expression
analysis, the variation between and within measurement platforms
for all genes under investigation using a subset of drugs was
analyzed. The correlation between independent biological assays
was as good as qPCR readouts (Fig. 5B).
Driving SAR of a chemical genetics hits using microfluidic
arrays
The principal advantage of a cell-based screen is that it
represents an unbiased picture of both known and unknown
cellular pathways that a molecule can modulate. The disadvantage
of this empirical approach is that the target remains unknown. Hit
to lead and lead optimization is generally more efficient when the
target is known, thus target deconvolution is essential despite being
time consuming and tedious. During SAR expansion, derivative
molecules of the primary compound are made with a greater
potency than the starting hit molecule (parent hit). It is imperative
to monitor that these derivatives inhibit the same target or similar
MoA, meaning that they have a similar transcription fingerprint as
the parent hit molecule. In order to evaluate if SAR analyses can
be improved for a compound with anti-tubercular activity, we
evaluated the transcription fingerprint of a series of derivatives
around particular pharmacophores. We hypothesized that a
change in the transcription profile would indicate a change of
target or MoA. To investigate this, a subset of an SAR expansion
of NCE1, NCE2, and NCE3 were analyzed. SAR groups NCE1
and NCE2 showed a similar transcription fingerprint, indicating
that they probably were still ‘‘on target’’ (Fig. 6 & S2). The NCE3
series displayed more variability in expression in our feature
reduction microfluidic experiment; this is evident in both the
heatmap and the correlation matrix (Figure 6& S2). All derivatives
had anti-bacterial activity (Table 1).
Discussion
There is an urgent need for new therapeutic approaches to
antibiotic discovery as a result of the rapid emergence of multi-
resistance to existing drugs, which is further exacerbated by the
current gap in the development of new molecules. Phenotypic
screening has re-emerged as the standard anti-bacterial drug
discovery approach to avoid some of the attrition in target-based
lead identification. When successful, it provides lead compounds
with proven in vivo activity against the organism of interest [8,9].
This approach has produced a large set of starting chemical points
for anti-bacterial & anti-parasitic lead discovery [14,28–32].
However, the cost of not having a biochemical assay for whole
cell activity is that hit to lead and lead optimization becomes more
challenging.
It is more difficult to establish consistent structure-activity
relationships from phenotypic screens because whole-cell potency
is a composite result of several compound properties, such as
target affinity, cell permeability, efflux, and or intracellular
modifications. Nonetheless, evidence supports the effectiveness of
this approach in the identification of novel chemical classes with
anti-bacterial or anti-malarial activity [23,24,28–32]. The key to
success is a good chemical starting point and an adequate
progression path to identify the potential to become a drug as
quickly as possible.
The current study describes a more efficient tool for MoA
deconvolution by transcriptional profiling of compounds derived
from phenotypic screens using a microfluidic platform with
integrated fluidic circuits. We show that the approach is indeed
feasible from both a conceptual and practical point of view. A
major goal was to identify a minimal set of genes that can be used
as biomarkers for MoA deconvolution on an amenable miniatur-
ized assay. Analysis of the whole genome bacterial transcriptional
responses to these compounds helped in selecting a set of
biomarker genes important in the general bacterial response to
antibiotics, which was utilized in the development of a routine
assay. Unsupervised grouping by hierarchical clustering revealed
gene clusters whose expression profile for these inhibitors was
consistent with previous studies on the MoA of these agents. More
importantly, the clustering grouped together inhibitors with a
similar mode of action.
A common theme, in all compound expression fingerprints was
the remarkable over representation of the genes in bacterial
defense, detoxification adaptation and virulence systems. Interest-
ingly, a majority of the functionally characterized biomarkers
appeared to be only indirectly related to the primary molecular
targets of most of the inhibitors used. These were largely identified
owing to their consistent expression pattern when exposed to
antibiotic stress. Some of the biomarkers included heat shock
proteins, toxin anti-toxin regulons, and detoxification systems
against reactive oxygen species. These findings are in line with an
increasingly more acknowledged mechanism of anti-bacterial
action where the accumulation of broadly toxic intermediates
and a suicidal derailing of central homeostatic system result in
bacterial death [4,7,8,27].
Hit to lead and lead optimization programs characteristically
result in the generation of multiple compound series. Whilst it is
important that cellular penetration, physiochemical profiles, and
target inhibition are maintained or improved during SAR
expansion, the gathering of this information is critical for good
lead selection. Biomarker gene expression fingerprinting revealed
that hit to lead and lead optimization could be guided in part by
transcriptional profiling of the SAR series using the biomarker
genes (Fig. 6). Derivatives of NCE1 and NCE2 showed similar
fingerprints to the primary hit molecules, suggesting that they
retained the same MoA. The tools described enable MoA
diagnosis whilst prioritizing compounds from an SAR library of
phenotypic screen derived leads. This will help in distinguishing
the new series from other compound classes based on the
transcriptional outcomes reflected in the gene expression by the
chemical perturbations. Although the microfluidics, helped in
tracking whether the novel compounds perturbed similar genes, it
fails to give more details regarding the exact mode of action. Once
the final compound has been identified, other techniques such as
spontaneous mutant generation followed by whole genome
sequencing and or affinity based target pull down studies need
to be employed to identify the actual target.
The low number of biomarker genes required for MoA
deconvolution and the establishment of a simple, robust and
routine assay highlights the value of this technology in anti-
infective drug discovery programs. As evidence to the potential
application of this diagnostic platform, Barczak and co-workers
recently underscored the application of drug RNA signatures for
rapid clinical diagnosis of antibiotic susceptibilities in a broad
range of bacterial pathogens [33]. The continued expansion of the
drug transcriptome (collection of transcriptional fingerprints
profiles generated by different chemical entities) using microfluidic
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arrays will generate a more composite resource for highly detailed
functional cataloguing of compounds; such as grouping com-
pounds that perturb similar sets of genes, as well as identifying sets
of deletion mutants that show sensitivity to similar sets of
compounds. Such tools can be used to augment phenotypic
screens and are likely to lead to a wider application of MoA
diagnostic assays in phenotypic screen campaigns. Although the
present study presents evidence from anti-bacterial compounds,
the vital components of this approach are not prokaryote specific.
Analogous approaches can be applied in eukaryotes for other
important medical indications such as the development of anti-
malarial and anti-parasitic drugs.
Supporting Information
Figure S1 A prediction correlation matrix using feature-
reduced data to validate the classification of individual
inhibitors. A heat map representation of gene expression
similarity matrix of chemical inhibitors using selected features.
The blue-red color scale shows the degree of correlation of drugs
expression profiles ranging from 21 to 1 respectively. All
expression values were transformed to log base 2. Periods
following drug names represent duplicates.
(TIF)
Figure S2 A correlation matrix based on Pearson
correlations of compounds from the same SAR library.
Note high levels of correlation as evident by the SAR clustering.
NCE1 SAR compounds and NCE2 SAR compounds form tight
clusters while NCE3 SAR compounds form two clusters. Red
blocks indicate correlations greater than 0.98, blue blocks indicate
correlations between 0.9–0.98, and white blocks are lower than
0.9.
(TIF)
Table S1 Minimal number of biomarker genes for MoA
deconvolution on a PCR array. Note the gene function were
as depicted in ,http://genolist.pasteur.fr/TubercuList/..
(DOCX)
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